Akèy › Alòpesi Areat
Etid klinik pou Alòpesi Areat ap rekrite nan Etazini
17 etid pou Alòpesi Areat ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Indianapolis, IN7 etid
- Miami, FL6 etid
- San Antonio, TX6 etid
- Omaha, NE5 etid
- New York City, NY4 etid
- Los Angeles, CA3 etid
- Troy, MI3 etid
- Spokane, WA3 etid
- Houston, TX3 etid
- Columbus, OH3 etid
- Portland, OR3 etid
- Irvine, CA3 etid
Pa eta
- Florid8 etid
- Illinois3 etid
- Indiana8 etid
- Kalifòni10 etid
- Maryland5 etid
- Massachusetts4 etid
- Michigan5 etid
- Nebraska5 etid
- New York6 etid
- North Carolina3 etid
- Ohio6 etid
- Oregon3 etid
- Pennsylvania3 etid
- South Carolina3 etid
- Texas7 etid
- Washington4 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
Ap rekriteFaz 2
Laj 18 a 50 · Tout sèks · Mizajou Sep 22, 2026 · NCT07533006A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Ap rekriteFaz 3
Laj 12 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06873945A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
Ap rekriteFaz 3
Laj 6 a 17 · Tout sèks · Mizajou Sep 17, 2026 · NCT07772492HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Sep 15, 2026 · NCT07049328A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
Ap rekriteFaz 3
Laj 12 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT07733765Dupilumab in the Treatment of Pediatric Alopecia Areata
Ap rekriteFaz 2
Laj 6 a 17 · Tout sèks · Mizajou Sep 2, 2026 · NCT05866562CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry
Ap rekriteEtid obsèvasyon
Laj 12 a 17 · Tout sèks · Mizajou Aug 17, 2026 · NCT06562270A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
Ap rekriteFaz 3
Laj 12 a 63 · Tout sèks · Mizajou Aug 3, 2026 · NCT06012240Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Jun 26, 2026 · NCT06747611Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
Ap rekriteFaz 2Volontè an sante akeyi
Laj 12 a 75 · Tout sèks · Mizajou Jun 22, 2026 · NCT05398809Regeneron AA Multicenter (Dupilumab)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 17, 2026 · NCT05551793A Study of LAD603 in Adults With Alopecia Areata
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou May 20, 2026 · NCT07311564A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Ap rekriteFaz 3
Laj 6 a 14 · Tout sèks · Mizajou Apr 28, 2026 · NCT07029828A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata
Ap rekriteFaz 1/2
Laj 18 a 55 · Tout sèks · Mizajou Mar 4, 2026 · NCT06826196CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Feb 9, 2026 · NCT05745389Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Feb 2, 2026 · NCT07242638Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Ap rekriteFaz 3
Laj 12 a 17 · Tout sèks · Mizajou Jan 28, 2026 · NCT07133308Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.